Skip to main content

Radiotherapy is one of the main treatments for cancer and is used as an independent treatment or in combination with surgery and/or systemic treatment (i.e. chemotherapy). The goal is to cure cancer, to augment the prognosis, or to palliate symptoms.

Radiation therapy has a biological effect on the DNA and the inflammatory status of the tumor. The side effects are decreased by modern techniques that allow to paint the dose more precisely.

The proposed treatment is discussed with the patient at consultation, usually after multidisciplinary discussion. The radiation oncologist follows the patient throughout the radiotherapy treatment and takes part in the follow-up after therapy, in close collaboration with the other health professionals.

Research projects

Our dedicated research page provides a more comprehensive overview of our research activities. Below we show some examples of current research projects.
 

Project 1

Swall PEG study: Patient reported outcomes in term of swallowing and quality of life after prophylactic versus reactive percutaneous endoscopic gastrostomy tube placement in oropharyngeal cancer patients treated with definitive chemoradiotherapy.
  • Project leaders : Tatiana Dragan, Dirk Van Gestel
  • Trial sponsor : Institut Jules Bordet
  • Funding : Les Amis de l’Institut Bordet
  • Collaboration : CHU Saint-Pierre, Universitair Ziekenhuis Gent

Project 2

Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial.

Project 3

ProCaLung  – The Project on Cancer of the Lung
  • Project leadersFlorian Charlier, Luigi Moretti
  • Trial sponsor: Belgian College of Physicians for Radiotherapy Centers
  • Funding: Belgian College of Physicians for Radiotherapy Centers and “Les Amis de l’Institut Bordet”
  • Collaboration: Other ProCaLung Team members: Xavier Geets (Cliniques Universitaires Saint-Luc), Maarten Lambrecht (UZLeuven), Yolande Lievens (UZGent), Vincent Remouchamps (CHU-UCL Namur - Site Ste Elizabeth)

Project 4

Contribution to the study of stereotaxic radiotherapy and its immunomodulatory effect in the treatment of pancreatic cancers.
  • Project leaders : Bouchart ChristelleLuigi Moretti
  • Trial sponsor : Institut Jules Bordet
  • Funding : « Fonds de la Recherche Scientifique – FNRS », « Les Amis de l’Institut Bordet », « Fondation contre le Cancer ».
  • Collaboration : Hopital Erasme, Molecular Immunology Lab (MIU, Institut J. Bordet ULB), Laboratory of Medical and Molecular Oncology (LMMO, VUB), CHU Saint-Pierre, CHR Namur and all the hospitals of the ULB network.

Project 5

Randomized trial to quantify the efficacy of the Safetac® product Mepitel® Film on the prevention of radiodermatitis in the inguinal fold.
  • Project leader : Van de Ven Gitte
  • Trial sponsor : Institut Jules Bordet
  • Funding : Mölnlycke

Projet 6

Evaluation of a clinical decision support protocol during radiotherapy for H&N cancer patients
  • Projectleaders : Filipa Rodrigues Sousa, Younes Jourani
  • Trial sponsor : Institut Jules Bordet

Our team

Head of Department
- Prof 
Dirk Van Gestel : head and neck tumours, skin tumours, non-malignant tumours, sarcomas, breast tumours.

Medical Physics Department
The radiotherapy physics’ team is part of the central Medical Physics Department of the Institute.
Prof Nick Reynaert, Head of Medical Physics Department:
Mr Younes Jourani, Responsible for physics in radiotherapy:

Head of technologists
-
Mrs Monica Somoano Tarno

Radiation Oncologists
- Dr Imane Ahrouch: breast and gynaecological tumours, brachytherapy

- Hamza AlGhamdi : neurological and oligometastatic tumours
- Dr Sylvie Beauvois : head and neck and skin tumours
- Dr 
Christelle Bouchart : pancreatic and neurological tumours
Dr Christine Collen : neurological and thoracic tumours
- Dr Antoine Desmet : breast and skin tumours, intraoperative radiotherapy and brachytherapy
- Dr 
Tatiana Dragan : head and neck tumours, sarcomas

- Prof. Philippe Martinive : neurological, digestive and pediatric tumours
- Prof. 
Luigi Moretti : digestive and thoracic tumours
- Dr 
François-Xavier Otte : urological tumours
- Dr 
Catherine Philippson : breast tumours and intraoperative radiotherapy
- Dr Robbe Van den Begin : oligometastatic, urological and digestive tumours
Dr Daphné Van Kampen : breast tumours and lymphomas
- Prof. Honorary 
Paul Van Houtte : thoracic and gynecological tumours, non-malignant tumours, brachytherapy

- Dr Alex De Caluwé : Research consultant
- Prof. Philippe Lambin: Research Consultant

Radiation Oncologists in training
- Dr Mathilde Baré
- Dr Zineb Belbaraka
- Dr Sarah Bellal
- Dr Sofian Benkhaled
- Dr Elisa Bodson
- Dr Pauline De Bruyn
- Dr Marie-Elise Delavigne
- Dr Thomas Descamps
- Dr Emmanuel Fardeau
- Dr Hamza Ghassan
- Dr Carolina Gomes Da Silveira
- Dr Nicolas Jullian
- Dr Alizée Laverdure
- Dr Martin Mandelier
- Dr Michel Madeline

Radiotherapy Nurse Coach
The Nurse Coach in radiotherapy supports the patients in organizing their multidisciplinary care, in the first place for the patients referred by other centers.
- Mrs Ysabelle Houtekens - 
Maureen Billiet – Stefanie Van Daele

Quality Manager
- -

Administration
- Mrs Elodie Gevart
- Mrs 
Magali Anzil

10/08/2022

 Scientific publications

Barriers in education and professional development of Belgian medical imaging technologists and nurses working in radiotherapy: A qualitative study.

Authors : Sousa F, Vaandering A, Couto JG, Somoano M, Van Gestel D
Year : 2022
Journal : Radiography (Lond)
Volume : 28
Pages : 620-627

Oligorecurrent nodal prostate cancer: radiotherapy quality assurance of the randomized PEACE V-STORM phase II trial.

Authors : Achard V, Jaccard M, Vanhoutte F, Siva S, Heikkilä R, Dirix P, Liefhooghe N, Otte FX, Gomez-Iturriaga A, Berghen C, Shelan M, Conde-Moreno A, Campos FL, Papachristofilou A, Guckenberger M, Meersschout S, Putora PM, Zwahlen D, Couñago F, Scorsetti M, Eito C, Barrado M, Zapatero A, Muto P, Van De Voorde L, Lamanna G, Koutsouvelis N, Dipasquale G, Ost P, Zilli T
Year : 2022
Journal : Radiother Oncol

ProCaLung - Peer review in stage III, mediastinal node-positive, non-small-cell lung cancer: How to benchmark clinical practice of nodal target volume definition and delineation in Belgium<sup>☆</sup>.

Authors : Charlier F, Descamps T, Lievens Y, Geets X, Remouchamps V, Lambrecht M, Moretti L
Year : 2022
Journal : Radiother Oncol
Volume : 167
Pages : 57-64

Clinical Outcomes After Proton Beam Therapy for Locally Advanced Non-Small Cell Lung Cancer: Analysis of a Multi-institutional Prospective Registry.

Authors : Jongen A, Charlier F, Baker K, Chang J, Hartsell W, Laramore G, Mohindra P, Moretti L, Redman M, Rosen L, Tsai H, Van Gestel D, Vargas C, Rengan R
Year : 2022
Journal : Adv Radiat Oncol
Volume : 7
Pages : 100767

Restoring p53 Function in Head and Neck Squamous Cell Carcinoma to Improve Treatments.

Authors : de Bakker T, Journe F, Descamps G, Saussez S, Dragan T, Ghanem G, Krayem M, Van Gestel D
Year : 2022
Journal : Front Oncol
Volume : 11
Pages : 799993